Rangeley's Strategic Q1 Moves
Rangeley Capital Significantly Adjusts Investment Portfolio, Boosting Driven Brands and Leggett & Platt Stakes in Q1
Anonymous
Key Points
1
Delek US Holdings remains Rangeley's 7th-largest position, but the stake declined 41.2% in Q1 to 60,000 shares, representing about 2.5% of Rangeley's portfolio with an end-of-period value of roughly $2.704 million.
2
Rangeley's stake in Net Lease Office Properties equated to 0.78% of the company and was worth about $1.323 million, following an addition of 46,390 shares to reach 114,870 total; the position ranks 27th in Rangeley's portfolio and Net Lease makes up about 1.2% of Rangeley's holdings.
3
Driven Brands Holdings became Rangeley's largest holding, with 625,500 shares purchased for about $7.888 million, constituting roughly 7.2% of the portfolio.
4
Rangeley also initiated a position in Inhibikase Therapeutics by acquiring 220,000 shares, valued at about $370,000, representing around 0.17% ownership.
5
Beyond Rangeley's moves, other major investors increased Leggett & Platt holdings in the prior quarter, including Vanguard Group Inc. (up to 18,990,042 shares, a 1.5% increase during Q4) and Geode Capital Management (3,173,733 shares), with further increases by Invenomic Capital Management, Charles Schwab Investment Management, and Wellington Management Group.
Rangeley Capital LLC made a series of bold portfolio moves in the first quarter, most notably building a new stake in Driven Brands Holdings worth about $7.89 million — making it the firm's single largest holding at roughly 7.2% of the portfolio, according to Watchlist News.
The Connecticut-based hedge fund also boosted its Leggett & Platt position by 56.7%, adding 77,070 shares to reach 213,000 total, valued at about $2.1 million. At the same time, it cut its Delek US Holdings stake by 41.2% and opened a brand-new position in Inhibikase Therapeutics.
Driven Brands Becomes Rangeley's Biggest Bet
Rangeley's most significant Q1 move was buying 625,500 shares of Driven Brands Holdings for roughly $7.888 million, according to Watchlist News. That single purchase pushed Driven Brands to the top of the firm's entire portfolio.
No other holding came close to that weight. The position represents about 7.2% of Rangeley's total portfolio. It signals strong conviction in the auto-services company, which operates brands like Maaco and Meineke.
Leggett & Platt and Net Lease Stakes Jump Higher
Rangeley grew its Leggett & Platt stake by 56.7% in Q1, buying 77,070 more shares. The firm now holds 213,000 shares worth about $2.1 million. Other major investors also added to their Leggett & Platt positions last quarter. Vanguard Group raised its stake to 18,990,042 shares — a 1.5% increase — while Geode Capital Management held 3,173,733 shares, per Watchlist News.
Rangeley also added 46,390 shares of Net Lease Office Properties, lifting its total to 114,870 shares worth about $1.32 million. That stake equals 0.78% ownership of the company. The position now ranks 27th in Rangeley's portfolio and makes up about 1.2% of its holdings.
Rangeley Opens Fresh Position in Inhibikase Therapeutics
The firm initiated a brand-new stake in Inhibikase Therapeutics, picking up 220,000 shares valued at around $370,000, according to Watchlist News. That gives Rangeley about 0.17% ownership of the small biotech company.
Rangeley also took a new position in Revolution Medicines during Q1, making it the firm's second-largest holding with 66,700 shares purchased, per Watchlist News. These two new biotech bets show the firm is actively scouting growth in the life-sciences space.
Delek US Holdings Stake Cut Nearly in Half
Not every move was a buy. Rangeley slashed its Delek US Holdings position by 41.2% during Q1, ending the quarter with just 60,000 shares. Those shares were worth about $2.704 million at period-end, per Watchlist News.
Despite the sharp cut, Delek remains Rangeley's 7th-largest holding. It still accounts for about 2.5% of the total portfolio. The trim suggests the firm is rotating capital away from the energy refiner and toward consumer services and biotech.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
11
Reach
25
A
AnonymousAuthor
